|
|
|
hPL
Elisa
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Pregnancy
Diagnosis |
Singleton
Pregnancy |
Twin
Pregnancy |
|
10
- 12 Weeks |
0.05 - 1.00
mg/l |
|
|
12
- 14 Weeks |
0.10 - 1.7
mg/l |
|
|
14
- 16 Weeks |
0.3 - 2.8
mg/l |
|
|
16
- 18 Weeks |
0.5 - 3.5
mg/l |
|
|
18
- 20 Weeks |
0.9 - 4.0
mg/l |
|
|
20
- 22 Weeks |
1.1 - 5.0
mg/l |
2.2 - 7.0
mg/l |
|
22
- 24 Weeks |
1.3 - 5.8
mg/l |
3.0 - 8.1
mg/l |
|
24
- 26 Weeks |
1.6 - 6.7
mg/l |
3.6 - 9.2
mg/l |
|
26
- 28 Weeks |
2.0 - 7.7
mg/l |
4.1 - 10.3
mg/l |
|
28
- 30 Weeks |
2.7 - 8.5
mg/l |
4.6 - 11.7
mg/l |
|
30
- 32 Weeks |
3.2 - 9.5
mg/l |
5.0 - 13.0
mg/l |
|
32
- 34 Weeks |
3.7 - 10.1
mg/l |
5.4 - 15.1
mg/l |
|
34
- 36 Weeks |
4.0 - 10.7
mg/l |
5.7 - 17.8
mg/l |
|
36
- 38 Weeks |
4.3 - 11.2
mg/l |
5.9 - 19.7
mg/l |
|
38
- 40 Weeks |
4.4 - 11.7
mg/l |
5.8 - 19.6
mg/l |
|
40
- 42 Weeks |
4.3 - 11.6
mg/l |
-- -
-- |
3.5 Warnings and precautions for users
1.
CAUTION: Test methods are not available which can offer complete assurance that
Hepatitis B virus, Human Immunodeficiency Virus (HIV/HTLV-III/LAV), or other
infectious agents are absent from the reagents in this kit. Therefore, all human
blood products, including patient samples, should be considered potentially
infections. Handling and disposal should be in accordance with the procedures
defined by an appropriate national biohazard safety guideline or regulation,
where it exists (e.g., USA Center for Disease Control/National Institute of
Health Manual, "Biosafety in Microbiological and Biomedical
Laboratories," 1984).
2.
Avoid contact with Stop Solution
0.5M H2SO4. It may cause skin irritation and burns.
3.
Replace caps on reagents immediately. Do not switch caps.
4.
Solutions containing additives or preservatives, such as sodium azide,
should not be used in the enzyme reaction.
5.
Do not pipette reagents by mouth.
6.
For in vitro diagnostic use only.
7.
Do not mix or use components from kits with different lot numbers.
4 SPECIMEN COLLECTION AND PREPARATION
2.
Specimens should be capped and may be stored for up to 5 days at 2-8°C
prior to assaying. Specimen held for a longer time should be frozen only once at
-20°C prior to assay. Thawed samples should be inverted several times prior to
testing.
5 PERFORMANCE OF THE ASSAY
5.1 General remarks
1.
All reagents and specimens must be allowed to come to room temperature
before use. All reagents must be mixed without foaming.
2.
Once the test has been started, all steps should be completed without
interruption.
3.
Use new disposable tips for each specimen.
4.
Absorbance is a function of the incubation time and temperature. Before
starting the assay, it is recommended that all reagents be ready, caps removed,
all needed wells secured in holder, etc. This will ensure equal elapsed time for
each pipetting step without interruption.
5.
The present hPL kit is adjusted to give an absorption for calibrator 4 of
1,200 to 2,000 within 10 minutes at room temperature (22°C). If that absorption
value is above the upper performance limit of your microtiterplate
spectrophotometer or lower than 1.200, you can reduce or extend the incubation
time of the final enzymatic formation of color accordingly. As a general rule
the enzymatic reaction is linearly proportional to time and temperature. This
makes interpolation possible for fixed physico-chemical conditions.
5.2 Sample preparation
Before starting the assay
the sample must be prediluted 1:100 with Zero Calibrator:
1.
Add for each
sample, which is to be measured, 1ml of Zero Calibrator in one test tube.
2.
Add 10µl of
each sample to the appropriate test tube. Mix all tubes for 10 seconds on an
Vortex mixer (avoid foaming).
Procedural
Note
1.
Manual Pipetting: It is recommended that no more than 32 wells be used
for each assay run. Pipetting of all calibrators, samples, and controls should
be completed within 3 minutes.
2.
Automated Pipetting: A full plate of 96 wells may be used in each assay
run. However, it is recommended
that pipetting of all calibrators, samples, and controls be completed within 3
minutes.
3. All calibrators, samples, and controls should be run in duplicate concurrently so that all conditions of testing are the same
5.3 Assay Procedure
1.
Secure the desired number of
coated Microtiterwells in the holder.
2.
Dispense 100
µl Anti-hPL Enzyme-Conjugate into
each well.
3.
Dispense 10
µl hPL Calibrators, controls and
prediluted serum specimen with new
disposable tips into appropriate wells.
4.
Thoroughly mix for 10
seconds. It is important to have a complete mixing in this step.
5.
Incubate for 30 minutes at room temperature.
6.
Briskly shake out the
contents of the wells.
7.
Rinse the wells 5 times with
distilled water.
8.
Strike the wells sharply on
absorbent paper to remove residual water droplets.
9.
Add 100
µl of Substrate Solution to each
well.
10.
Incubate for 10 minutes at room temperature.
11.
Stop the enzymatic reaction
by adding 50 µl of Stop Solution to each well.
12.
Read the OD at 450±10 nm with a microtiterplate reader.
Final
Reaction Stability
It
is recommended that the wells be read within 10 minutes following step 11.
1.
Calculate the average absorbance values for each set of reference
calibrators, controls and patient samples.
2.
Construct a calibrator curve by plotting the mean absorbance obtained
from each reference calibrator against its concentration in mg/L with absorbance
value on the vertical(Y) axis and concentration on the horizontal (X) axis.
3.
Using the mean absorbance value for each sample determine the
corresponding concentration of hPL in mg/L from the calibrator curve. Depending
on experience and/or the availability of computer capability, other methods of
data reduction may be employed.
6.1 Specificity
|
Antigen
tested |
Equivalent
to hPL |
|
|
hCG |
2000 IU/l |
undetectable |
|
AFP |
300 KIU/l |
undetectable |
|
hGH |
100 µg/l |
undetectable |
| Prolactin |
200
µg/l |
undetectable |
The
minimal detectable concentration of hPL by this assay is estimated to be 0.3
mg/l.
6.3.1 Intra Assay Precision
Within-run
precision was determined by replicate determinations of three different control
sera in one assay. The within-assay variability is shown below:
| Serum
Sample |
1 |
2 |
3 |
| Number
of Replicates |
18 |
18 |
18 |
| Mean
HPL (mg/l) |
0.66 |
2.34 |
6.24 |
| Standard
Deviation |
0.04 |
0.13 |
0.42 |
| Coefficient
of Variation (%) |
6.06 |
5.55 |
6.73 |
6.3.2 Inter Assay Precision
Between-run
precision was determined by replicate measurements of three different control
sera in several different assays. The between-assay variability is shown below:
| Serum
Sample |
1 |
2 |
3 |
| Number
of Replicates |
39 |
24 |
24 |
| Mean
HPL (mg/L) |
0.68 |
2.52 |
6.87 |
| Standard
Deviation |
0.06 |
0.18 |
0.39 |
| Coefficient
of Variation (%) |
8.82 |
7.14 |
5.67 |
6.4 Recovery and linearity
6.4.1 Recovery
Various
patient serum samples of know hPL levels were mixed and assayed in duplicate.
The
average recovery was 101.17%.
| Expected |
Observed |
|
| Concentration |
Concentration |
|
| mg/l |
mg/l |
%
Recovery |
|
1.51 |
1.43 |
94.7 |
|
2.60 |
2.81 |
108.0 |
|
3.38 |
3.17 |
93.8 |
|
3.97 |
3.97 |
100.0 |
|
5.84 |
6.13 |
105.0 |
|
6.76 |
7.13 |
105.5 |
6.4.2 Linearity
Two
patient samples were serially diluted with Zero Calibrator in a linearity study.
The
average recovery was 99.7%.
| Patient |
|
Expected Concentration |
Observed Concentration |
|
| Number |
Dilution |
mg/l |
mg/l |
%
Recovery |
| 1 |
1:50 |
|
14.16 |
|
| |
1:100 |
7.08 |
6.69 |
94.5 |
| |
1:200 |
3.54 |
3.52 |
99.4 |
| |
1:400 |
1.77 |
1.78 |
100.6 |
| |
1:800 |
0.88 |
0.99 |
112.5 |
| |
|
|
|
|
| 2 |
1:50 |
|
15.97 |
|
| |
1:100 |
7.98 |
6.42 |
80.5 |
| |
1:200 |
3.99 |
4.04 |
101.3 |
| |
1:400 |
1.99 |
1.99 |
100.0 |
| |
1:800 |
0.99 |
1.08 |
109.1 |
6.5 Hook effect
In
this assay, no hook effect is observed up to 700 mg/l of hPL.
6.6 Quality control
Good
laboratory practice requires that controls are run with each calibration curve.
A statistically significant number of controls should be assayed to establish
mean values and acceptable ranges to assure proper performance. Controls
containing azide should not be used.
7 Limitations of procedure
1.
Reliable and
reproducible results will be obtained when the assays procedure is carried out
with a complete understanding of the package insert instructions and with
adherence to good laboratory practice.
2.
The results
obtained from the use of this kit should be used only as an adjunct to other
diagnostic procedures and information available to the physician.
3.
The wash
procedure is critical. Insufficient washing will result in poor precision and
falsely elevated absorbance readings.
8
FLOW CHART
|
|
Standards |
Sample(s) Controls
|
|
Standards
(0-4) ml Controls/Samples
ml Anti-hPL-HRP
conjugate ml |
10 - 100 |
- 10 100 |
|
and
Incubate 30 min. at RT Rinse wells 5 x with water |
||
|
Substrate
solution |
100 |
100 |
|
Incubate 10 minutes at RT |
||
|
Stop
solution |
50 |
50 |
|
Read:
450 nm |
||
|